Therapeutic Interventions Clause Samples

Therapeutic Interventions. Therapeutic interventions or non-treatment interactions will be used by staff, including Support Persons and Activity Therapists prior to initiating a Mental Health Watch when clinically indicated.

Therapeutic Interventions. (a) General Community Based Services which may include: i. Condition management and a whole person approach to single or multiple chronic conditions based on goals and needs identified by the individual; ii. General outpatient services; iii. Medication Management for: (A) Mental Health disorders (when providing services for individuals with co-occurring mental and substance use disorders). (B) Substance Use disorders: (i) Includes pharmacotherapy for adults diagnosed with opioid dependence, alcohol dependence or nicotine dependence and without medical contraindications. Publicly funded programs will not discriminate in providing access to Services for individuals using medications to treat and manage addictions. (ii) Pharmacotherapy, if prescribed, should be provided in addition to and directly linked with psychosocial treatment and support. iv. Detoxification for individuals with substance use disorders under OAR 415-012-0000 through 415-012-0090 and 415- 050-0000 through 415-050-0095. Supportive pharmacotherapy may be provided to manage the symptoms and adverse consequences of withdrawal, based on a systematic assessment of symptoms and risk of serious adverse consequences related to the withdrawal process. v. Meaningful individual and family involvement; and vi. Services provided by peers. The County is encouraged to make available services and supports delivered by peers. If the County lacks these services and supports, the County is encouraged to develop a plan to expand the array of services and supports provided by peers in a manner that is consistent with their Local Plan, or Regional Health Improvement Plan (RHIP) as applicable, and in consultation with AMH.

Therapeutic Interventions. CONTRACTOR shall provide individual and group 17 therapeutic interventions based on clinical assessments to participants who demonstrate a need.

Therapeutic Interventions. CONTRACTOR shall provide individual, and group therapeutic interventions based on clinical assessments to Participants who demonstrate a need and who do not qualify for managed care. Therapeutic activity shall utilize best practices and evidence-based approaches as approved by ADMINISTRATOR. Staff providing individual and group therapeutic interventions are to be supervised by a clinical supervisor. Therapeutic individual and group intervention, when provided, shall be documented in the Participant’s chart in the progress notes.

Therapeutic Interventions. The Supplier shall provide therapeutic interventions, which shall be required due to the high risk and traumatic nature of some job roles. The Buyer shall inform the Supplier at Call-Off stage whether this Service is required. The Buyers Occupational Health Service may also provide therapeutic Interventions. The supplier shall carry out an initial psychological assessment of the User within forty eight (48) hours of referral to provide the most clinically appropriate therapeutic intervention. The Supplier shall be able to provide the following therapies: Cognitive Behavioural Therapy (CBT); Trauma Focussed CBT; Eye Movement Desensitization and Reprocessing (EMDR); and Other approved and appropriate specialist interventions. The Supplier shall: Arrange the first counselling session appointment within forty eight (48) hours of agreeing that a therapeutic intervention is an appropriate form of treatment; Ensure the first session of the therapeutic intervention takes place within five (5) days of referral; Provide a fast-track referral option where circumstances require a therapeutic intervention session in advance of the standard appointment window. A fast track referral appointment shall take place within two (2) days of first referral; Ensure that the duration of the initial consultation and subsequent sessions are in line with clinical best practice; Ensure that when work-related stress is identified as an underlying issue, that assessment is carried out in conjunction with the Health and Safety Executive Management Standards; Provide immediate telephone counselling support and/or forward Buyers Personnel immediately to emergency NHS Primary Care/A&E where a User is presenting at risk i.e. ‘red flag’. Examples of such are, medical emergencies and the risk of self-harm; and Provide the first face-to-face therapeutic intervention session for urgent cases within twenty-four (24) hours of first contact. Where such therapeutic intervention Services are recommended by the Supplier for a User the maximum number of sessions shall be agreed and approved between the Supplier and Buyers prior to commencement. The Supplier shall ensure that they have access to a comprehensive UK wide network of counsellors available to deliver these Services. The Supplier shall ensure that premises are appropriate, safe and offer adequate levels of privacy to Users, if they provide face-to-face therapeutic intervention away from the Users normal place of work. The Supplier shall provi...

Therapeutic Interventions. The WHO criteria for the management of severe malaria were utilized as a guide to determine when animals were progressing towards severe disease and necessitated clinical and/or therapeutic intervention to ▇▇▇▇ off terminally severe outcomes [41]. Animals that developed clinical complications associated with severe malaria during the acute infection periods were administered a sub-curative antimalarial treatment of 1 mg/kg of artemether. Additionally, severe anemia (< 7 g/dl) was treated with IV fluid support and whole blood transfusion, also guided by YNPRC veterinarian recommendations and IACUC-approved procedures. After collecting the specimens for the post peak infection point (Figure 1A), blood-stage infections were cured with artemether administered at 4 mg/kg on the first day of treatment and 2 mg/kg/day for seven days thereafter. This ensured that subsequent blood-stage parasitemias detected in the animals were the result of relapses from the activation of hypnozoites, and not recrudescences of sub-patent, persisting blood-stage forms. Curative blood-stage treatment with artemether was also administered using this same regimen after each relapse, and a curative course of chloroquine (15 mg/kg/day for 3 days administered intramuscularly) and primaquine (1 mg/kg/day for 7 days administered orally) was administered at the end of the entire experiment to treat the blood stages and the hypnozoites, respectively. and archived. Data derived from blood and bone marrow samples were associated with the appropriate animal and experimental metadata via a barcode. All data associated with this study (clinical, experimental, SOPs and data dictionary to define all terms) were backed-up locally as well as off-site. The dataset supporting the conclusions of this article is included with the article as Supplementary File 1 and is also being made available via the freely accessible database, PlasmoDB [42] (▇▇▇▇://▇▇▇▇▇▇▇▇.▇▇▇), as no archival repositories exist for these types of data. This experiment is known in the deposited files as MaHPIC Experiment 4 (E04). Primary and relapsing parasitological profiles of Plasmodium cynomolgi B strain in M. mulatta during a 100-day experimental infection. Intravenous inoculation of approximately 2,000 freshly isolated salivary gland sporozoites produced patent infections within 10 to 12 days (mean ± SE = 11.2 ± 0.37) consistent with previous literature (Figure 1B; [17, 32]). The maximum parasitemias during the primary infection...